Akebia therapeutics, inc. (AKBA)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
Operating activities:
Net loss

-279,659

-143,588

-73,671

-135,747

-60,716

-37,034

-13,167

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

2,245

899

617

296

96

49

1

Amortization of intangibles

36,401

1,522

-

-

-

-

-

Gain on extinguishment of debt and other liabilities

-

-

-

-

-

-

2,420

Amortization of debt issuance costs

-

-

-

-

-

-

8

Amortization of premium/discount on investments

819

1,232

-610

-494

-558

-268

-752

Non-cash interest expense

786

28

-

-

-

-

-

Non-cash operating lease expense

-2,229

-

-

-

-

-

-

Write-off of property and equipment

-2,053

-

-

-306

-

-

-

Non-cash merger expense

-

13,386

-

-

-

-

-

Fair value write-up of inventory sold

70,444

4,771

-

-

-

-

-

Write-down of inventory

7,112

-

-

-

-

-

-

Stock-based compensation

11,925

19,040

8,867

5,825

4,714

6,010

1,564

Deferred income taxes

-6,631

-28,338

-

-

-

-

-

Fair value of warrants issued for license

-

-

3,413

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable

22,198

-33,384

393

33,823

-

-

-

Inventory

29,142

-26

-

-

-

-

-

Prepaid expenses and other current assets

-10,541

977

4,193

-428

1,001

686

217

Other long-term assets

-4,917

-903

991

2

976

179

-

Other assets

-

-

-

-

-

-

125

Accounts payable

1,372

13,717

4,959

-274

231

1,307

296

Accrued expense

-27,351

55,482

21,974

20,703

4,646

2,754

1,976

Operating lease liabilities

2,531

-

-

-

-

-

-

Deferred revenue

-39,739

-66,935

-17,665

197,289

-

-

-

Deferred rent

-

418

314

2,411

41

28

-

Net cash used in operating activities

-257,441

-97,494

-56,159

57,906

-52,407

-27,483

-11,332

Investing activities:
Acquisition of business, net of acquired cash and restricted cash

-

-6,147

-

-

-

-

-

Purchase of equipment

6,655

1,606

1,622

2,662

414

229

19

Proceeds from the maturities of available for sale securities

153,110

243,269

149,998

162,376

63,901

12,585

1,990

Proceeds from sales of available for sale securities

64,721

13,000

5,000

-

-

-

-

Purchase of available for sale securities

-

224,216

330,636

147,009

77,175

77,708

13,396

Net cash provided by investing activities

211,176

36,594

-177,260

12,705

-13,688

-65,352

-11,425

Proceeds from the issuance of redeemable convertible preferred stock, net of issuance costs

-

-

-

-

-

-

40,047

Proceeds from the issuance of common stock, net of issuance costs

25,785

95,452

114,580

66,736

82,750

104,328

5

Proceeds from the sale of stock under employee stock purchase plan

383

482

353

106

220

-

-

Proceeds from the exercise of stock options

560

647

1,312

124

130

-

-

Retirement of treasury stock

426

-

-

-

-

-

-

Proceeds from the issuance of debt, net

77,668

-

-

-

-

-

-

Payments on debt

15,000

-

-

-

-

-

-

Repurchase of treasury stock

-

-

-

-

-

162

-

Payments received on promissory notes issued in exchange for shares of common stock

-

-

-

-

-

237

-

Payments on capital lease obligations

-

19

5

20

7

3

-

Net cash provided by financing activities

88,970

96,562

116,240

66,946

83,093

104,400

42,331

Increase in cash, cash equivalents, and restricted cash

42,705

35,662

-117,179

137,557

16,998

11,565

19,574

Non-cash financing activities
Fair value of shares and equity awards issued in acquisition

-

527,754

-

-

-

-

-

Conversion of series A, series B and series C preferred stock into common stock

-

-

-

-

-

244,727

4,944

Accretion of preferred stock to redemption value

-

-

-

-

-

86,899

55,886

Unpaid initial public offering issuance costs

-

-

-

-

-

-

857

Unpaid follow-on offering costs

-

-

-

12

102

-

-

Assets acquired under capital lease

-

-

-

-

12

-

12